Therapeutic FoxL2-TT vaccination suppressed tumor progression compared with control vector (4T1, P = 0.0062; BR5, P = 0.0028) in BR5-FOXL2 and 4T1-FOXL2 tumor–bearing mice (Figure 6, D and F) and improved mouse survival (BR5, P < 0.02; 4T1, P < 0.04) (Supplemental Figure 7). Here, FOXL2 is linked to neoplasm.